Drug intelligence / Profile preview

rMal d 1

Development stage
Phase 2
Lead developer
Biomay
Modality
Recombinant Proteins and Enzymes
Administration
Oral, Intradermal, Sublingual, Intranasal, Ophthalmic
01

Overview

rMal d 1 is the recombinant form of Mal d 1, a major allergenic protein from apple (Malus domestica) belonging to the pathogenesis-related class 10 (PR-10) proteins. It is a Bet v 1-like protein with a molecular weight of approximately 17.5 kDa and is recognized as one of the primary allergens responsible for apple allergy, particularly in individuals sensitized to birch pollen due to structural cross-reactivity. rMal d 1 is used primarily in diagnostic assays and research settings to detect specific IgE antibodies in patients suspected of having apple allergy or oral allergy syndrome (OAS). The mechanism involves IgE-mediated hypersensitivity reactions upon exposure. Recombinant production allows for standardized testing and controlled challenge studies[4][6][3].

Other names
recombinant Mal d 1Malus domestica allergen 1PR-10 proteinPR10 proteinPR 10 proteinBet v 1-like protein
02

Targets

IgE (Immunoglobulin E)

Beyond the preview

Go deeper on rMal d 1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on rMal d 1.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call